REAL-LIFE CLINICAL UTILITY OF RAMUCIRUMAB FOR THE TREATMENT OF PATIENTS WITH DISSEMINATED GASTRIC ADENOCARCINOMA: PRELIMINARY REVIEW OF THE EXPERIENCE OF BLOKHIN RUSSIAN CANCER RESEARCH CENTRE
Angiogenesis has become an important target in the treatment of solid tumors and anti-angiogenic agents are a promising approach to cancer therapy. Ramucirumab, an anti-angiogenic agent specifically targeting vascular endothelial growth factor receptor-2 (VEGFR-2). I...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2017-11-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/2180 |
| _version_ | 1797841586846957568 |
|---|---|
| author | N. S. Besova T. A. Titova V. A. Gorbunova O. O. Gordeeva A. A. Tryakin A. V. Snegovoy R. Yu. Nasyrova A. A. Rumyantsev E. A. Voroshilova E. V. Artamonova |
| author_facet | N. S. Besova T. A. Titova V. A. Gorbunova O. O. Gordeeva A. A. Tryakin A. V. Snegovoy R. Yu. Nasyrova A. A. Rumyantsev E. A. Voroshilova E. V. Artamonova |
| author_sort | N. S. Besova |
| collection | DOAJ |
| description | Angiogenesis has become an important target in the treatment of solid tumors and anti-angiogenic agents are a promising approach to cancer therapy. Ramucirumab, an anti-angiogenic agent specifically targeting vascular endothelial growth factor receptor-2 (VEGFR-2). In April 2014, the FDA approved ramucirumab as a single agent or in combination with paclitaxel for treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC) that has progressed on or after prior fluoropyrimidine – or platinumcontaining chemotherapy based on data of REGARD and RAINBOW trials.We evaluated the progression free (PFS), overall survival (OS) and safety of ramucirumab in patients (pts) with advanced GC in routine clinical practice From June 2016 to 20 Sep 2017 40 pts with advanced GC were treated with ramucirumab in the second line treatment as single agent (8 pts) or in combination with paclitaxel (26 pts) in N.N.Blokhin National medical research center of oncology.Median PFS (MPFS) and median OS (MOS) was 1,8 and 7,6 mons for monotherapy group. For combination group MPFS was 5,02 mons, MOS was not reached. Ramucirumab had an acceptable safety profile Our data are similar to the data of REGARD and RAINBOW trials. |
| first_indexed | 2024-04-09T16:33:41Z |
| format | Article |
| id | doaj.art-c2a7979bf8de497a9de468175d5de089 |
| institution | Directory Open Access Journal |
| issn | 2079-701X 2658-5790 |
| language | Russian |
| last_indexed | 2024-04-09T16:33:41Z |
| publishDate | 2017-11-01 |
| publisher | Remedium Group LLC |
| record_format | Article |
| series | Медицинский совет |
| spelling | doaj.art-c2a7979bf8de497a9de468175d5de0892023-04-23T06:57:01ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902017-11-01014303810.21518/2079-701X-2017-14-30-382157REAL-LIFE CLINICAL UTILITY OF RAMUCIRUMAB FOR THE TREATMENT OF PATIENTS WITH DISSEMINATED GASTRIC ADENOCARCINOMA: PRELIMINARY REVIEW OF THE EXPERIENCE OF BLOKHIN RUSSIAN CANCER RESEARCH CENTREN. S. Besova0T. A. Titova1V. A. Gorbunova2O. O. Gordeeva3A. A. Tryakin4A. V. Snegovoy5R. Yu. Nasyrova6A. A. Rumyantsev7E. A. Voroshilova8E. V. Artamonova9Blokhin Russian Cancer Research Centre, Ministry of HealthBlokhin Russian Cancer Research Centre, Ministry of HealthBlokhin Russian Cancer Research Centre, Ministry of HealthBlokhin Russian Cancer Research Centre, Ministry of HealthBlokhin Russian Cancer Research Centre, Ministry of HealthBlokhin Russian Cancer Research Centre, Ministry of HealthBlokhin Russian Cancer Research Centre, Ministry of HealthBlokhin Russian Cancer Research Centre, Ministry of HealthBlokhin Russian Cancer Research Centre, Ministry of HealthBlokhin Russian Cancer Research Centre, Ministry of HealthAngiogenesis has become an important target in the treatment of solid tumors and anti-angiogenic agents are a promising approach to cancer therapy. Ramucirumab, an anti-angiogenic agent specifically targeting vascular endothelial growth factor receptor-2 (VEGFR-2). In April 2014, the FDA approved ramucirumab as a single agent or in combination with paclitaxel for treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC) that has progressed on or after prior fluoropyrimidine – or platinumcontaining chemotherapy based on data of REGARD and RAINBOW trials.We evaluated the progression free (PFS), overall survival (OS) and safety of ramucirumab in patients (pts) with advanced GC in routine clinical practice From June 2016 to 20 Sep 2017 40 pts with advanced GC were treated with ramucirumab in the second line treatment as single agent (8 pts) or in combination with paclitaxel (26 pts) in N.N.Blokhin National medical research center of oncology.Median PFS (MPFS) and median OS (MOS) was 1,8 and 7,6 mons for monotherapy group. For combination group MPFS was 5,02 mons, MOS was not reached. Ramucirumab had an acceptable safety profile Our data are similar to the data of REGARD and RAINBOW trials.https://www.med-sovet.pro/jour/article/view/2180advanced gastric cancersecond line treatmentramucirumab |
| spellingShingle | N. S. Besova T. A. Titova V. A. Gorbunova O. O. Gordeeva A. A. Tryakin A. V. Snegovoy R. Yu. Nasyrova A. A. Rumyantsev E. A. Voroshilova E. V. Artamonova REAL-LIFE CLINICAL UTILITY OF RAMUCIRUMAB FOR THE TREATMENT OF PATIENTS WITH DISSEMINATED GASTRIC ADENOCARCINOMA: PRELIMINARY REVIEW OF THE EXPERIENCE OF BLOKHIN RUSSIAN CANCER RESEARCH CENTRE Медицинский совет advanced gastric cancer second line treatment ramucirumab |
| title | REAL-LIFE CLINICAL UTILITY OF RAMUCIRUMAB FOR THE TREATMENT OF PATIENTS WITH DISSEMINATED GASTRIC ADENOCARCINOMA: PRELIMINARY REVIEW OF THE EXPERIENCE OF BLOKHIN RUSSIAN CANCER RESEARCH CENTRE |
| title_full | REAL-LIFE CLINICAL UTILITY OF RAMUCIRUMAB FOR THE TREATMENT OF PATIENTS WITH DISSEMINATED GASTRIC ADENOCARCINOMA: PRELIMINARY REVIEW OF THE EXPERIENCE OF BLOKHIN RUSSIAN CANCER RESEARCH CENTRE |
| title_fullStr | REAL-LIFE CLINICAL UTILITY OF RAMUCIRUMAB FOR THE TREATMENT OF PATIENTS WITH DISSEMINATED GASTRIC ADENOCARCINOMA: PRELIMINARY REVIEW OF THE EXPERIENCE OF BLOKHIN RUSSIAN CANCER RESEARCH CENTRE |
| title_full_unstemmed | REAL-LIFE CLINICAL UTILITY OF RAMUCIRUMAB FOR THE TREATMENT OF PATIENTS WITH DISSEMINATED GASTRIC ADENOCARCINOMA: PRELIMINARY REVIEW OF THE EXPERIENCE OF BLOKHIN RUSSIAN CANCER RESEARCH CENTRE |
| title_short | REAL-LIFE CLINICAL UTILITY OF RAMUCIRUMAB FOR THE TREATMENT OF PATIENTS WITH DISSEMINATED GASTRIC ADENOCARCINOMA: PRELIMINARY REVIEW OF THE EXPERIENCE OF BLOKHIN RUSSIAN CANCER RESEARCH CENTRE |
| title_sort | real life clinical utility of ramucirumab for the treatment of patients with disseminated gastric adenocarcinoma preliminary review of the experience of blokhin russian cancer research centre |
| topic | advanced gastric cancer second line treatment ramucirumab |
| url | https://www.med-sovet.pro/jour/article/view/2180 |
| work_keys_str_mv | AT nsbesova reallifeclinicalutilityoframucirumabforthetreatmentofpatientswithdisseminatedgastricadenocarcinomapreliminaryreviewoftheexperienceofblokhinrussiancancerresearchcentre AT tatitova reallifeclinicalutilityoframucirumabforthetreatmentofpatientswithdisseminatedgastricadenocarcinomapreliminaryreviewoftheexperienceofblokhinrussiancancerresearchcentre AT vagorbunova reallifeclinicalutilityoframucirumabforthetreatmentofpatientswithdisseminatedgastricadenocarcinomapreliminaryreviewoftheexperienceofblokhinrussiancancerresearchcentre AT oogordeeva reallifeclinicalutilityoframucirumabforthetreatmentofpatientswithdisseminatedgastricadenocarcinomapreliminaryreviewoftheexperienceofblokhinrussiancancerresearchcentre AT aatryakin reallifeclinicalutilityoframucirumabforthetreatmentofpatientswithdisseminatedgastricadenocarcinomapreliminaryreviewoftheexperienceofblokhinrussiancancerresearchcentre AT avsnegovoy reallifeclinicalutilityoframucirumabforthetreatmentofpatientswithdisseminatedgastricadenocarcinomapreliminaryreviewoftheexperienceofblokhinrussiancancerresearchcentre AT ryunasyrova reallifeclinicalutilityoframucirumabforthetreatmentofpatientswithdisseminatedgastricadenocarcinomapreliminaryreviewoftheexperienceofblokhinrussiancancerresearchcentre AT aarumyantsev reallifeclinicalutilityoframucirumabforthetreatmentofpatientswithdisseminatedgastricadenocarcinomapreliminaryreviewoftheexperienceofblokhinrussiancancerresearchcentre AT eavoroshilova reallifeclinicalutilityoframucirumabforthetreatmentofpatientswithdisseminatedgastricadenocarcinomapreliminaryreviewoftheexperienceofblokhinrussiancancerresearchcentre AT evartamonova reallifeclinicalutilityoframucirumabforthetreatmentofpatientswithdisseminatedgastricadenocarcinomapreliminaryreviewoftheexperienceofblokhinrussiancancerresearchcentre |